Marrow raises $173M for siRNA drug competing with CRISPR therapy for sickle cell
When the FDA approved two gene therapies for sickle cell disease in December 2023, many drugmakers viewed it as the end of the story and shelved their programs for the condition. Yet three years on ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.